Case Report

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography

Bartosz Olechowski, Alexander Ashby, Nalyaka Sambu, Michael Mahmoudi, and Nick Curzen

Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

Correspondence should be addressed to Bartosz Olechowski; drolechowski@gmail.com

Received 20 June 2016; Revised 24 August 2016; Accepted 28 August 2016

Academic Editor: Michael S. Firstenberg

Copyright © 2016 Bartosz Olechowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to P\textsubscript{2}Y\textsubscript{12} inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not routine practice to assess the functional response to these agents. However, concern over functional hyporesponsiveness to clopidogrel has led to widespread uptake of prasugrel and ticagrelor as the default P\textsubscript{2}Y\textsubscript{12} inhibitor after stent implantation in patients with acute coronary syndrome. Here we report, for the first time, 3 cases in which patients who have had ST exhibit hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor.

1. Introduction

Stent thrombosis (ST) is a major complication of percutaneous coronary intervention (PCI), occurring in 2.0–2.9% of patients within 22 months [1]. Although uncommon, ST is associated with significant mortality of up to 45% [2]. Dual antiplatelet therapy (APT) with aspirin and P\textsubscript{2}Y\textsubscript{12} inhibitor has become the default strategy in patients undergoing coronary stent implantation to reduce the risk of ST. However, a cohort of patients may have an inadequate functional response to P\textsubscript{2}Y\textsubscript{12} [3, 4] and are more likely to sustain ischaemic events including ST [5].

There is particular concern about clopidogrel in this regard [6, 7]. The established link between functional hyporesponsiveness to clopidogrel and ischaemic events, including ST, in patients receiving coronary stents has triggered the development of more potent and faster-acting P\textsubscript{2}Y\textsubscript{12} inhibitors. Two large randomised trials have demonstrated reduction in ischaemic endpoints for prasugrel and ticagrelor when compared to clopidogrel in acute coronary syndrome (ACS) patients undergoing PCI, albeit at the price of increased bleeding [8, 9]. In response to these data and earlier studies demonstrating quicker onset and more potent and more homogeneous responses of healthy volunteers and stable patients to prasugrel and ticagrelor compared to clopidogrel, many PCI centres in the UK have switched from clopidogrel to either prasugrel or ticagrelor as their default. Interestingly the incidence of prasugrel hyporesponsiveness is estimated to be 25% using flow cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation in ACS patients [10, 11]. In the CREST registry, out of 6 patients who were found to be hyporesponsive to prasugrel, only 3 responded adequately to ticagrelor [6].

We present for the first time 3 cases who had experienced definite ST after drug eluting stent (DES) implantation who demonstrated functional hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor, using a previously well validated test, short thromboelastography (sTEG) [12–15]. sTEG uses a novel parameter, percentage clotting inhibition (%CI) in the AA or ADP channel for clotting inhibition by aspirin or P\textsubscript{2}Y\textsubscript{12} inhibitors, respectively. The formula for %CI by aspirin is 100 − (AUC\textsubscript{15}(AA)/AUC\textsubscript{15}(Thrombin) × 100) and for %CI by P\textsubscript{2}Y\textsubscript{12} inhibitors is 100 − (AUC\textsubscript{15}(ADP)/AUC\textsubscript{15}(Thrombin) × 100) [14]. Threshold %CI of <50 in
the AA channel and <30 in the ADP channel was used to define hyporesponsiveness to aspirin and $P_2Y_{12}$ inhibitors, respectively.

2. Case Report

Patient 1 is a 74-year-old male with type 2 diabetes mellitus and previous anterior ST elevation myocardial infarction (STEMI) treated with a single drug eluting stent (DES) in the circumflex artery. He presented with proximal stent occlusion 2043 days after his index PCI while on aspirin 75 mg once daily. He was successfully treated with plain old balloon angioplasty (POBA) and bare metal stent (BMS) insertion. Subsequently he underwent platelet function testing using sTEG. Initially our patient was started on aspirin 150 mg daily and clopidogrel 75 mg daily. Forty-two days later, the assay revealed an adequate response to aspirin (%CI 71) but suboptimal response to clopidogrel (%CI 17). Therefore, prasugrel 5 mg daily was commenced as patient was borderline for response to aspirin (%CI 1) after 36 days of treatment and the dose was uptitrated to 10 mg daily. Subsequent test, 105 days later, revealed suboptimal response again (%CI 9). As a result, the patient was commenced on ticagrelor 90 mg twice daily without initial loading and restested after 85 days of treatment. Similarly, his reading revealed hyporesponsiveness (%CI 1) (Figure 1). Due to development of dyspnoea while on ticagrelor, the patient was finally left on prasugrel 10 mg daily for life. After this episode, he was treated with cardiac resynchronisation therapy and defibrillation due to severe ischaemic cardiomyopathy but is currently alive, having suffered no further ST or other ischaemic events.

Patient 2 is a 62-year-old male smoker with hyperlipidaemia and positive family history for premature coronary artery disease who originally presented with a non-ST-elevation myocardial infarction (NSTEMI) for which he had PCI with two DES implanted in the left anterior descending artery (LAD). He represented 671 days later with ST while on aspirin 75 mg once daily. Both vessels required final management strategy. In addition to this, no other results from Verify Now assay [21, 22].

Our case series demonstrates three cases of patients with acute stent thrombosis who were found to be hyporesponsive to all three commonly available $P_2Y_{12}$ receptor inhibitors. To the best of our knowledge, this is the first time that a series of such cases has been described. Two previously published case reports have illustrated patients with dual thienopyridine resistance to clopidogrel and prasugrel [16, 17]. In both cases, the patient was subsequently shown to have an adequate response to the ticagrelor. Orban et al. suggested that the response to ticagrelor may be due to its properties as an active drug, compared with prasugrel and clopidogrel which are prodrugs requiring hepatic cytochrome bioactivation prior to $P_2Y_{12}$ inhibition [17]. Based upon both early studies reporting superior potency, speed of onset and consistency of responses to prasugrel and ticagrelor versus clopidogrel in both volunteers and stable patients [18, 19], and subsequent large scale randomised trials, in many PCI centres, prasugrel and ticagrelor have become the default $P_2Y_{12}$ agent. The assumption from some interventionists is that prasugrel and ticagrelor are not associated with functional hyporesponsiveness (also known as “resistance”). However, recent data suggest that functional resistance does indeed occur in association with these agents [II, 20].

Our case series describe for the first time the concept of functional resistance to all three commonly available $P_2Y_{12}$ inhibitors. These data were obtained using short TEG, a well described and validated modification of TEG platelet mapping assay [10–15]. Our group has previously described the reproducibility of sTEG and has demonstrated the value of comparing the ADP-induced clotting response to that achieved using kaolin stimulation. This method has the advantage that there is a built-in reference, both numerical and visual, of the strength of the clot in response to ADP compared to the maximum clot strength achieved by kaolin. We have also used sTEG to describe discrepancies between these results from Verify Now assay [21, 22].

One limitation of our case series is that we were not able to objectively prove patients’ compliance with medications, although we appreciate that it might have implications on final management strategy. In addition to this, no other...
platelet function assays (i.e., Verify Now) were used to confirm our results.

These cases suggest that some patients experiencing ST may exhibit functional resistance to all 3 of the currently available oral $P_2Y_{12}$ inhibitors. As well as adding weight to the argument in favour of measuring individual responses to $P_2Y_{12}$ inhibitors, with the intention of possibly avoiding stents in patients who do not respond to them, it also raises interesting questions about the mechanism of hyporesponsiveness.
Figure 2: Short thromboelastography traces showing adequate response to aspirin 75 mg daily and hyporesponse to $P_2Y_{12}$ inhibitors in second patient. (a) Patient 2 clotting response to AA when on 75 mg daily aspirin, producing a $\%CI(AA)$ of 61, an adequate response to aspirin. (b) Patient 2 clotting response to ADP when on 75 mg clopidogrel daily, producing a $\%CI(ADP)$ of 21 (nonresponse to clopidogrel). (c) Patient 2 clotting response to ADP when on 10 mg prasugrel daily, producing a $\%CI(ADP)$ of 17 (nonresponse to prasugrel). (d) Patient 2 clotting response to ADP when on 90 mg ticagrelor twice daily, producing a $\%CI(ADP)$ of $-21$ (nonresponse to ticagrelor).

Further data are required to investigate whether this observation in such patients could be due to a paucity of receptor numbers, a functional flaw in the receptor activation, or perhaps even a lack of availability of such drugs at the receptor.

**Competing Interests**

Bartosz Olechowski, Alexander Ashby, Nalyaka Sambu, and Michael Mahmoudi declare that they have no competing interests. Nick Curzen received unrestricted research grants...
from Boston Scientific, Haemonetics; Heartflow, St. Jude Medical, and Medtronic; speaker fees/consultancy from Haemonetics, St. Jude Medical, Abbott Vascular, and Heartflow; and travel sponsorship from Biosensors, Abbott, and Lilly/D-S.

**References**

[1] F. D'Ascenzo, M. Bollati, F. Clementi et al., “Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses,” *International Journal of Cardiology*, vol. 167, no. 2, pp. 575–584, 2013.

[2] I. Iakovou, T. Schmidt, E. Bonizzoni et al., “Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents,” *The Journal of the American Medical Association*, vol. 293, no. 17, pp. 2126–2130, 2005.

[3] P. A. Gurbel, K. P. Bliden, B. L. Hiatt, and C. M. O’Connor, “Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity,” *Circulation*, vol. 107, no. 23, pp. 2908–2913, 2003.

[4] A. A. Pettersen, H. Arnesen, and I. Seljeflot, “A brief review on high on-aspirin residual platelet reactivity,” *Vascular Pharmacology*, vol. 67–69, pp. 6–9, 2015.

[5] D. Aradi, A. Kirtane, L. Bonello et al., “Bleeding and stent thrombosis on P2Y$_{12}$-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention,” *European Heart Journal*, vol. 36, no. 27, pp. 1762–1771, 2015.

[6] N. Sambu, A. Radhakrishnan, H. Dent et al., “Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry,” *Heart*, vol. 98, no. 9, pp. 706–711, 2012.

[7] D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives,” *Journal of the American College of Cardiology*, vol. 49, no. 14, pp. 1505–1516, 2007.

[8] S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes. TRITON-TIMI 38 Investigators,” *The New England Journal of Medicine*, vol. 357, no. 20, pp. 2001–2015, 2007.

[9] L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes. PLATO Investigators,” *The New England Journal of Medicine*, vol. 361, no. 11, pp. 1045–1057, 2009.

[10] A. D. Michelson, A. L. Frelinger, E. Braunwald et al., “Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial,” *European Heart Journal*, vol. 30, no. 14, pp. 1753–1763, 2009.

[11] L. Bonello, M. Pansieri, J. Mancini et al., “High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes,” *Journal of the American College of Cardiology*, vol. 58, no. 5, pp. 467–473, 2011.

[12] U. S. Tantry, K. P. Bliden, and P. A. Gurbel, “Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation,” *Journal of the American College of Cardiology*, vol. 46, no. 9, pp. 1705–1709, 2005.

[13] R. M. Craft, J. J. Chavez, S. J. Bresee, D. C. Wortham, E. Cohen, and R. C. Carroll, “A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation,” *Journal of Laboratory and Clinical Medicine*, vol. 143, no. 5, pp. 301–309, 2004.

[14] A. R. Hobson, G. W. Petley, K. D. Dawkins, and N. Curzen, “A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography,” *Platelets*, vol. 18, no. 7, pp. 497–505, 2007.

[15] N. Sambu, A. Hobson, and N. Curzen, “‘Short’ thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility,” *Platelets*, vol. 22, no. 3, pp. 210–216, 2011.

[16] I. Xanthopoulos, E. F. Stavrou, G. KassiMis, P. Goudas, and D. Alexopoulos, “Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report,” *Platelets*, vol. 24, no. 3, pp. 239–241, 2013.

[17] M. Orban, J. Riegger, M. Joner et al., “Dual thienopyridine-low-dose aspirin strategy in patients with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor,” *Platelets*, vol. 23, no. 5, pp. 395–398, 2012.

[18] S. D. Wiviott, E. M. Antman, K. J. Winters et al., “Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial,” *Circulation*, vol. 113, no. 25, pp. 3366–3373, 2005.

[19] S. Husted, H. Emanuelsen, S. Heptinstall, P. M. Sandset, M. Wickens, and G. Peters, “Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin,” *European Heart Journal*, vol. 27, no. 9, pp. 1038–1047, 2006.

[20] J. M. Siller-Matula, B. Akca, T. Neunteufl et al., “Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor,” *Platelets*, vol. 27, no. 4, pp. 373–377, 2016.
[21] V. Khanna, P. C. J. Armstrong, T. D. Warner, and N. Curzen, "Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: insights using short thromboelastography," *Platelets*, vol. 26, no. 7, pp. 689–692, 2015.

[22] V. Khanna, A. Hobson, R. Mikael, N. Sambu, N. Englyst, and N. Curzen, "Does the VerifyNow P2Y12 assay overestimate 'therapeutic response' to clopidogrel? Insights using short thromboelastography," *Thrombosis and Haemostasis*, vol. III, no. 6, pp. 1150–1159, 2014.